Health Catalyst, Inc. (HCAT) 股票分析

公司概述

Health Catalyst, Inc. operates within the healthcare sector as a provider of data and analytics technology and services specifically tailored for healthcare organizations across the United States. The company's business model is segmented into Technology and Professional Services, offering the ignite data and analytics platform which delivers a single comprehensive environment for clients. In terms of scale, the enterprise maintains a market capitalization of $74.32M with an annual revenue (TTM) of $311.14M and employs a workforce of 1200 individuals. These valuation and revenue figures indicate that the company currently operates as a small-cap entity with a relatively modest market presence compared to larger industry peers.

财务健康

The company reported a revenue of $311.14M for the trailing twelve months, yet recorded a net income of $-177,974,000 and an EBITDA of $-5,167,000, revealing a significant structural cost burden that severely erodes profitability before reaching the bottom line. Despite the substantial operating losses, the company generated positive free cash flow of $10.73M, which suggests a degree of operational liquidity and the ability to generate cash from core activities independent of accounting earnings. The gross margin stands at 49.7%, indicating that the company retains nearly half of its revenue after direct costs, while the operating margin of -4.3% and profit margin of -57.2% highlight substantial inefficiencies in overhead management and overall profit generation. On the balance sheet, Health Catalyst holds $95.73M in cash against $171.24M in debt, resulting in a highly leveraged position with a debt-to-equity ratio of 69.67. Although the current ratio is 1.89, indicating that short-term assets are nearly double current liabilities and suggesting adequate immediate liquidity coverage, the high leverage remains a critical constraint. Furthermore, the return on equity is -58.3% and the return on assets is -4.0%, metrics that demonstrate the management team has been ineffective at generating value for shareholders or utilizing the company's asset base to produce returns.

估值评估

The trailing twelve-month P/E ratio is listed as N/A due to the lack of earnings, while the forward P/E is 6.37, implying that the market is pricing in a significant turnaround in future profitability expectations. The price-to-book ratio of 0.30 suggests that the stock is trading at a substantial discount relative to its book value, reflecting investor concerns about the company's ability to recover from its current financial distress. Alternative valuation metrics such as a price-to-sales ratio of 0.24 and an EV/EBITDA of -29.00 further underscore the speculative nature of the valuation, as the negative multiples indicate that traditional earnings-based comparisons are not currently applicable. Regarding trading range, the 52-week high is $5.06 and the 52-week low is $0.97, meaning the current price sits at a level that reflects a deep discount from recent highs but remains above the absolute bottom of its annual trading band. The stock exhibits a beta of 1.81, which signifies that its price volatility is significantly higher than that of the broader market, amplifying potential gains but also magnifying downside risk during periods of market correction.

Growth & Income

Revenue growth year-over-year has declined by -6.2%, while earnings growth is N/A due to the company's continued losses, indicating that the business is currently contracting rather than expanding its top line. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders and instead retains all earnings, which are currently insufficient to fund growth without external capital. The negative revenue growth combined with the absence of dividend payments illustrates a growth and income profile characterized by contraction and a reliance on retained cash reserves or debt financing to sustain operations.